 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Key Links:
By Topic: Search: |
The Body Covers: The XV International AIDS Conference
HIV Infection and Antiretroviral Therapy in Patients Over 50
July 12, 2004 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Experts estimate that 10 to 17% of AIDS cases in the United States occurs in people over 50 years of age. Between 1990 and 2001, the cumulative number of AIDS cases reported to the U.S. Centers for Disease Control and Prevention in people aged 50 or older quintupled, from just over 16,000 to more than 90,000.1 Studies show that older patients respond well to highly active antiretroviral therapy (HAART) both virologically and immunologically, although mortality is higher.2 This retrospective study from Spain compared older HIV-infected patients (>60 years old) to younger ones (<35 years old). There were 31 patients in the older group and 71 patients in the younger group. Patients were seen over a period of 7 years. The older patients were more likely to be male (100% vs. 84%). The HIV risk factors for the younger group were sexual route and intravenous drug use whereas the risks were mostly unknown for the older patients. The older patients usually presented later, with a lower CD4+ cell count (209 cells/mm3 vs. 405 cells/mm3). Once on HAART, the older patients tended to have more drug-related side effects, which eventually required treatment modification. There were no differences in the rates of opportunistic infections, however, the mortality rate was higher for the elderly. The older patients also had a higher rate of hospitalization. Older patients may not perceive themselves to be at risk for HIV, and may not seek HIV testing, while primary care providers taking care of older patients may overlook this issue and feel it is unnecessary to discuss sexually transmitted diseases and safe-sex practices with them. All prevention, support and treatment services must begin to address the specific needs of the older population. In addition, clinical trials for antiretrovirals should be designed to look specifically at this group of patients. Footnotes
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Authored by: J Alonso, M Tejeda, A Salinas, E Alonso, D Blazquez, P Rivas, A Goyenechea, M Górgolas, M L Fernández-Guerrero
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.
|
Email
Glossary
Print-FriendlyThe Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
